In vitro assays for evaluation of drug activity against Leishmania spp.

Research in Microbiology

Volumn 155, Issue 4, 2004, Pages 224-230

  Fumarola, Luciana ^a   Spinelli, Rosa ^a   Brandonisio, Olga ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Drug evaluation; Leishmania; Leishmaniasis

Indexed keywords

ACID PHOSPHATASE; AMPHOTERICIN B; MEGLUMINE ANTIMONATE; MILTEFOSINE; NUCLEOTIDE; PENTAMIDINE; RADIOACTIVE ELEMENT; STIBOGLUCONATE SODIUM;

AMASTIGOTE; ASSAY; COLORIMETRY; DOG; DRUG ACTIVITY; DRUG RESISTANCE; FLOW CYTOMETRY; LEISHMANIA; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SCREENING; SHORT SURVEY; TRANSGENICS;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG EVALUATION, PRECLINICAL; LEISHMANIA; PARASITIC SENSITIVITY TESTS;

CANIS FAMILIARIS; PROTOZOA;

EID: 2442515288     PISSN: 09232508     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resmic.2004.01.001     Document Type: Short Survey

References (64)

1. Abdullah S.M., Flath B., Presber H.W. Comparison of different staining procedures for the flow cytometric analysis of U-937 cells infected with different Leishmania-species. J. Microbiol. Meth. 37:1999;123-138
2. Alvar J., Canavate C., Gutierrez-Solar B., Jimenez M., Laguna F., Lopez-Velez R., Molina R., Moreno J. Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin. Microbiol. Rev. 10:1997;298-319
3. Armson A., Kamau S.W., Grimm F., Reynoldson J.A., Best W.M., MacDonald L.M., Thompson R.C.A. A comparison of the effects of a benzimidazole and the dinitroanilines against Leishmania infantum. Acta Trop. 73:1999;303-311
4. Avila J.L., Avila A., Polegre M.E. Inhibitory effects of sinefungin and its cycling analog on the multiplication of Tripanosoma cruzi isolates. Am. J. Trop. Med. Hyg. 48:1993;112-119
5. Avlonitis N., Lekka E., Detsi A., Koufaki M., Calogeropoulou T., Scoulica E., Siapi E., Kyrikou I., Mavromoustakos T., Tsotinis A., Grdadolnik S.G., Makriyannis A. Antileishmanial ring-substituted ether phospholipids. J. Med. Chem. 46:2003;755-767
6. Bates P.A. Complete developmental cycle of Leishmania mexicana in axenic culture. Parasitology. 108:1994;1-9
7. Berens R.L., Brun R., Krassner S.M. A simple monophasic medium for axenic culture of hemoflagellates. J. Parasitol. 62:1976;360-365
8. Berg K., Zhai L., Chen M., Kharazmi A., Owen T.C. The use of a water-soluble formazan complex to quantitate the cell number and mitochondrial function of Leishmania major promastigotes. Parasitol. Res. 80:1994;235-239
9. Berman J. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 16:2003;397-401
10. Bodley A.L., McGarry M.W., Shapiro T.A. Drug cytotoxicity assay for African trypanosomes and Leishmania species. J. Infect. Dis. 172:1995;1157-1159
11. Brandonisio O., Carelli G., Ceci L., Consenti B., Fasanella A., Puccini V. Canine leishmaniasis in the Gargano promontory (Apulia, South Italy). Eur. J. Epidemiol. 8:1992;273-276
12. Brandonisio O., Spinelli R. Immune response to parasitic infections - an introduction. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2:2002;193-199
13. Brandonisio O., Fumarola L., Maggi P., Cavaliere R., Spinelli R., Pastore G. Evaluation of a rapid immunochromatographic test for serodiagnosis of visceral leishmaniasis. Eur. J. Clin. Microbiol. Infect. Dis. 21:2002;461-464
14. Bray P.G., Barrett M.P., Ward S.A., de Koning H.P. Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future. Trends Parasitol. 19:2003;232-239
15. Brochu C., Wang J., Roy G., Messier N., Wang X.Y., Saravia N.G., Ouellette M. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob. Agents Chemother. 47:2003;3073-3079
16. Brun R., Kunz C. In vitro drug sensitivity test for Trypanosoma brucei subgroup bloodstream trypomastigotes. Acta Trop. 46:1989;361-368
17. Buckner F.S., Verlinde C.L., La Flamme A.C., Van Voorhis W.C. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β -galactosidase. Antimicrob. Agents Chemother. 40:1996;2592-2597
18. Callahan H.L., Portal A.C., Deveraux R., Grogl M. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 41:1997;818-822
19. Carriò J., Riera C., Gàllego M., Portùs M. In vitro activity of pentavalent antimony derivatives on promastigotes and intracellular amastigotes of Leishmania infantum strains from humans and dogs in Spain. Acta Trop. 79:2001;179-183
20. Carrio J., Portus M. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol. 2:2002;11. Epub 2002 May 02
21. Chalfie M., Tu Y., Euskirchen G., Ward W.W., Prasher D.C. Green fluorescent protein as a marker for gene expression. Science. 263:1994;802-805
22. Chan M.M., Bulinski J.C., Chang K.P., Fong D. A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein. Parasitol. Res. 89:2003;266-271
23. Chan-Bacab M.J., Balanza E., Deharo E., Munoz V., Garcia R.D., Pena-Rodriguez L.M. Variation of leishmanicidal activity in four populations of Urechites andrieuxii. J. Ethnopharmacol. 86:2003;243-247
24. Collins L.A., Torrero M.N., Franzblau S.G. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:1998;344-347
25. Coombs G.H., Hart D.T., Capaldo J. Leishmania mexicana: Drug sensitivies of promastigotes and transforming amastigotes. J. Antimicrob. Chemother. 11:1983;151-162
26. Croft S.L., Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8:2002;319-342
27. Croft S.L., Yardley V., Kendrick H. Drug sensitivity of Leishmania species: Some unresolved problems. Trans R. Soc. Trop. Med. Hyg. 96:2002;127-129
28. Davies C.R., Kaye P., Croft S.L., Sundar S. Leishmaniasis: New approaches to disease control. BMJ. 326:2003;377-382
29. Delgado G., Puentes F., Moreno A., Patarroyo M.E. Flow cytometry, a useful tool for detecting the lethal effect of pentamidine on Leishmania viannia complex promastigote forms. Pharmacol. Res. 44:2001;281-286
30. Faraut-Gambarelli F., Piarroux R., Deniau M., Giusiano B., Marty P., Michel G., Faugere B., Dumon H. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: A study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 41:1997;827-830
31. Gaspar R., Opperdoes F.R., Preat V., Roland M. Drug targeting with polyalkylcyanoacrylate nanoparticles: In vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann. Trop. Med. Parasitol. 86:1992;41-49
32. Gramiccia M., Gradoni L., Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann. Trop. Med. Parasitol. 86:1992;613-620
33. Grogl M., Thomason T.N., Franke E.D. Drug resistance in leishmaniasis: Its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:1992;117-126
34. Guerin P.J., Olliaro P., Sundar S., Boelaert M., Croft S.L., Desjeux P., Wasunna M.K., Bryceson A.D.M. Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2:2002;494-501
35. Guimond C., Trudel N., Brochu C., Marquis N., El Fadili A., Peytavi R., Briand G., Richard D., Messier N., Papadopoulou B., Corbeil J., Bergeron M.G., Legare D., Ouellette M. Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res. 31:2003;5886-5896
36. Ha D.S., Schwarz J.K., Turco S.J., Beverley S.M. Use of the green fluorescent protein as a marker in transfected Leishmania. Mol. Biochem. Parasitol. 77:1996;57-64
37. Jacobs W.R. Jr., Barletta R.G., Udani R., Chan J., Kalkut G., Sosne G., Kieser T., Sarkis G.J., Hatfull G.F., Bloom B.R. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science. 260:1993;819-822
38. Jackson J.E., Tally J.D., Ellis W.Y., Mebrahtu Y.B., Lawyer P.G., Were J.B., Reed S.G., Panisko D.M., Limmer B.L. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. from patients unresponsive to pentavalent antimony therapy. Am. J. Trop. Med. Hyg. 43:1990;464-480
39. Kamau S.W., Nunez R., Grimm F. Flow cytometry analysis of the effect of allopurinol and the dinitroaniline compound (Chloralin) on the viability and proliferation of Leishmania infantum promastigotes. BMC Pharmacol. 1:2001;1. Epub 2001 Apr 05
40. Kamau S.W., Grimm R., Hehl A.B. Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro. Antimicrob. Agents and Chemother. 45:2001;3654-3656
41. Khan K.M., Rasheed M., Ullah Z., Hayat S., Kaukab F., Choudhary M.I., ur-Rahman A., Perveen S. Synthesis and in vitro leishmanicidal activity of some hydrazides and their analogues. Bioorg. Med. Chem. 11:2003;1381-1387
42. Laguna F., Lopez-Velez R., Pulido F., Salas A., Torre-Cisneros J., Torres E., Medrano F.J., Sanz J., Pico G., Gomez-Rodrigo J., Pasquau J., Alvar J. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B, Spanish HIV-Leishmania Study Group. AIDS. 13:1999;1063-1069
43. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., Sacks D. Evidence that the high incidence of treatment failure in Indian Kala-Azar is due to the emergence of antimoni-resistant strains of Leishmania donovani. J. Infect. Dis. 180:1999;564-567
44. Maarouf M., de Kouchkovsky Y., Brown S., Petit P.X., Robert-Gero M. In vivo interference of paromomycin with mithochondrial activity of Leishmania. Exp. Cell. Res. 232:1997;339-348
45. Mauel J., Ransijn A. Leishmania spp.: Mechanisms of toxicity of nitrogen oxidation products. Exp. Parasitol. 87:1997;98-111
46. Mc Fadden D.C., Seeber F., Boothroyd J.C. Use of Toxoplasma gondii expressing β -galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob. Agents Chemother. 41:1997;1849-1853
47. Mikus J., Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar blue. Parasitol. Int. 48:2000;265-269
48. Paredes R., Munoz J., Diaz I., Domingo P., Gurgui M., Closet B. Leishmaniasis in HIV infection. J. Postgrad. Med. 49:2003;39-49
49. Perez-Victoria F.J., Castanys S., Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob. Agents Chemother. 47:2003;2397-2403
50. Perez-Victoria F.J., Gamarro F., Ouellette M., Castanys S. Functional cloning of the miltefosine transporter: A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 272:2003;49965- 49971. Sep 27 [Epub]
51. Prasher D.C. Using GFP to see the light. Trends Genet. 11:1995;320-323
52. Raz B., Iten M., Grether-Buhler Y., Kaminsky R., Brun R. The Alamar blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop. 68:1997;139-147
53. Roberts W.L., Rainey P.M. Antileishmanial activity of sodium stibogluconate fractions. Antimicrob. Agents Chemother. 37:1993;1842-1846
54. Rosenthal E., Marty P. Recent understanding in the treatment of visceral leishmaniasis. J. Postgrad. Med. 49:2003;61-68
55. Roy G., Dumas C., Sereno D., Wu Y., Singh A.K., Tremblay M.J., Ouellette M., Olivier M., Papadopoulou B. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol. Biochem. Parasitol. 110:2000;195-206
56. Sacks D.L., Perkins P.V. Identification of an infective stage of Leishmania promastigotes. Science. 223:1984;1417-1419
57. Savoia D., Avanzini C., Conti S., Magliani V., Frazzi R., Polonelli L. In vitro leishmanicidal activity of a monoclonal antibody mimicking a yeast killer toxin. J. Eukaryot. Microbiol. 49:2002;319-323
58. Selzer P.M., Pingel S., Hsieh I., Ugele B., Chan V.J., Engel J.C., Bogyo M., Russell D.G., Sakanari J.A., McKerrow J.H. Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target. Proc. Natl. Acad. Sci. USA. 96:1999;11015-11022
59. Sereno D., Lemesre J.L. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 41:1997;972-976
60. Sereno D., Guilvard E., Maquaire S., Cavaleyra M., Holzmuller P., Ouaissi A., Lemesre J.L. Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: Implication for the spread of chemoresistance in endemic areas. Acta Trop. 80:2001;195-205
61. Sereno D., Roy G., Lemesre J.L., Papadopoulou B., Ouellette M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob. Agents Chemother. 45:2001;1168-1173
62. Singh N., Singh R.T., Sundar S. Novel mechanism of drug resistance in Kala Azar field isolates. J. Infect. Dis. 188:2003;600-607
63. Sundar S., Rai M. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15:2002;593-598
64. WHO. www.who.int/emc/diseases/leish/leisdisl.html